KOREA WHO

Cho Young-shik is the Chairman of the Board at SD Biosensor. He also serves as the Chairman of the Board at Bionote, the largest shareholder of SD Biosensor.

In the post-COVID-19 era, he is seeking new growth engines by diversifying diagnostic test items and pursuing corporate mergers and acquisitions.

He was born on June 30, 1961, in Gyeonggi-do.

He graduated from Yushin High School in Suwon, Gyeonggi, and earned his degree in veterinary medicine from Seoul National University. He obtained both his master’s and doctoral degrees in biochemistry from the graduate school of Seoul National University.

He joined Green Cross, where he worked in the development and marketing of diagnostic reagents, then moved to Viromed. In 1999, he founded SD (now Abbott Diagnostics Korea), a company specializing in human diagnostic reagents. In 2003, he founded Bionote, specializing in veterinary diagnostic products.

After SD was sold to a foreign company and SD Biosensor, the diagnostic equipment division, was spun off, he secured management control.

During the COVID-19 outbreak, he expanded sales in the diagnostic product market, boosting revenue to over KRW 1 trillion (US$ 721 million).

He considers technology to be the driving force behind business growth and competition. His management principle is to enter markets one step ahead of others.

He believes in the philosophy that “staying still leads to failure,” emphasizing constant change for survival.

#ChoYoungshik #SDBiosensor #Bionote #KoreanBiotech #DiagnosticReagents #COVID19Testing #MergersAndAcquisitions #VeterinaryDiagnostics #CorporateLeadership #BiotechInnovation